MONMOUTH JUNCTION, N.J., Oct. 17, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader commercializing its flagship CytoSorb®
extracorporeal cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, is
pleased to congratulate Kathleen Bloch, Chief Financial Officer (CFO) of CytoSorbents, as the
winner of the NJBIZ Public Company CFO of the Year Award, announced Friday, October 14th
at the annual awards ceremony.
The 2016 NJBIZ CFO of the Year
Awards celebrates New Jersey's financial executives at all levels who contribute to the
success of New Jersey's economic growth and stability.
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "We are very proud of Kathy
and this award that reflects her many accomplishments not just at CytoSorbents, but throughout her long and successful
career. Kathy's contributions to our company run far and wide, and include for example, helping to establish and execute
upon our global strategy, spearheading the up-listing to NASDAQ and ensuring ongoing SEC and Sarbanes Oxley compliance, and
managing the financing and financial needs of this rapidly growing, vertically integrated manufacturer of CytoSorb® that through
the effort of more than 70 employees over 2 continents, is saving lives and generating strong sales growth across a 40-country
network of distributors, strategic partners, and our own direct sales team. Congratulations again to Kathy for this well-deserved
award."
About NJBIZ
NJBIZ, New Jersey's
leading business journal, produces a weekly print edition with a circulation of more than 15,000 copies, as well as providing
24/7 business news coverage through its NJBIZ.com website and multiple daily e-newsletters. The publication, founded in
1987, is also well-known as the leader of numerous events honoring New Jersey's top business
professionals.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical
care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 40 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma,
lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high,
yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory
mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ
failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled
study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac
surgery. In early 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA
approval. CytoSorb® has been used safely in more than 14,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic
substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive
grant and contract funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Air Force,
the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood
Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based
upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including
CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's
websites: http://www.cytosorbents.com and
http://www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by
the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified
by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential,"
"continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the
forward-looking statements in this press release represent management's current judgment and expectations, but our actual
results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed
with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press
releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of
the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow us on Facebook and Twitter
Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytosorbents-congratulates-kathleen-bloch-as-njbiz-public-company-chief-financial-officer-of-the-year-300345629.html
SOURCE CytoSorbents Corporation